Repligen Insider Trades
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 0 · $0
- Sales
- 0 · $0
- Shares bought / sold
- 0 / 0
- Net activity
- Net buying $0
Repligen insider activity
Over the last 12 months, Repligen insiders reported 1 transaction on SEC Form 4: 0 open-market purchases and 0 sales. The most recent filing shows Douglass Brian Robb (CHIEF PRODUCT OFFICER) reporting a transaction in 700 shares on Oct 6, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put RGEN's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
RGEN insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Oct 6, 2026 | Douglass Brian RobbCHIEF PRODUCT OFFICER | Award | 700 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4